tretinoin, page-6

4,347 posts.
Date:
17/08/14
Time:
07:13:40
Post #:
13828438
IP:
120.149.xxx.xxx
KC - I've always thought that there might a 'third party' in the background watching over. I base this on that the company has stated that the trial is not designed to show statistical significance, so why do it otherwise, if not to show this?
My personal take on this, is that a third party is interested and after the results of the phase I, wanted to see the clinical effect for themselves. So rather than run an expensive time consuming large trial, POH offered a small phase II to highlight the differences particularly in irritation and effect.
If so, I expect a deal ready to be signed - subject to post trial outcomes.
I also expect it will be with a competitor to the market leading product.
The company will be ready to run with a significant phase III, will find it much easier to recruit participants and then straight to the FDA.
This will be a significant stage for POH. Apart from further external validation of TPM acceptance, it will highlight the diversity and dermatological scope of TPM.
This will be reflected by noticeable confidence reflected by the share price, IMO.


13
Report Quick reply Reply

POH (ASX)​

​

Price at posting:​

9.7¢​

Sentiment:​

Buy​

Disclosure:​

Held​

​

I certainly hope this is the way it plays out. I think shareholders are overdue for a large tick up in share price​